VMET
Versamet Royalties Corporation Common StockNASDAQBASIC MATERIALSOTHER PRECIOUS METALS & MINING
Key Statistics
Market Cap
$1.29B
P/E Ratio
38.35
EPS
$0.31
Beta
—
52W High
$15.00
52W Low
$9.10
50-Day MA
$11.33
200-Day MA
$11.18
Dividend Yield
—
Profit Margin
58.50%
Forward P/E
44.05
PEG Ratio
—
About Versamet Royalties Corporation Common Stock
Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company dedicated to the development of innovative therapeutics targeting serious and life-threatening diseases, utilizing its proprietary metalloenzyme-based technology platform. Focused on addressing unmet medical needs in the realms of fungal infections and oncology, Viamet is positioned as a key player in therapeutic innovation. With a robust pipeline supported by strategic partnerships and a strong intellectual property portfolio, the company is well-equipped to advance its clinical programs and maximize shareholder value, aiming to transform treatment paradigms in its targeted therapeutic areas.
Fundamentals
| Revenue (TTM) | $34.76M |
| Gross Profit (TTM) | $19.66M |
| EBITDA | $44.94M |
| Operating Margin | 135.60% |
| Return on Equity | 9.13% |
| Return on Assets | 7.47% |
| Revenue/Share (TTM) | $0.38 |
| Book Value | $2.50 |
| Price-to-Book | 3.52 |
| Price-to-Sales (TTM) | 37.14 |
| EV/Revenue | 24.15 |
| EV/EBITDA | 19.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 465.20% |
| Shares Outstanding | $108.59M |
| Float | $34.20M |
| % Insiders | 66.74% |
| % Institutions | 5.56% |
Historical Volatility
HV 10-Day
84.86%
HV 20-Day
73.95%
HV 30-Day
87.52%
HV 60-Day
75.73%
HV Rank
—
Volatility is currently contracting
More BASIC MATERIALS Stocks
Data last updated: 5/25/2026